摘要
背景:褪黑素是一种具有许多适用于治疗神经疾病的特性的分子。这些性质包括以下:氧和氮反应性物质的有效清除剂,抗炎症特征,免疫增强性质和昼夜节律性的调节。此外,神经疾病和精神障碍患者通常会发现低浓度的褪黑激素。在包括神经系统疾病(例如,阿尔茨海默氏病,帕金森病,多发性硬化症,肌萎缩性侧索硬化症,亨廷顿舞蹈病,癫痫症,头痛等)的各种病理学的实验模型中获得的阳性结果为以及心理和行为上的混乱(例如,自闭症谱系障碍,注意力缺陷多动障碍等),已经作为设计临床试验来研究褪黑激素在人类病理学中可能有用的基础,尽管从实验室工作台并不总是适用于病人的床边。 目的:在本文中,我们回顾那些描述在神经病理学领域中用于各种治疗目的的褪黑素给药的结果的论文。 结论:强烈的方法和适当剂量的褪黑激素的临床试验是必要的,以支持或拒绝褪黑素在神经系统疾病的有效性
关键词: 褪黑激素,阿尔茨海默病; 帕金森病,多发性硬化症,肌萎缩性侧索硬化症,亨廷顿病,自闭症谱系障碍,注意力缺陷多动症,头痛,癫痫,脊髓损伤,缺血性中风,睡眠障碍。
Current Medicinal Chemistry
Title:Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Volume: 24 Issue: 35
关键词: 褪黑激素,阿尔茨海默病; 帕金森病,多发性硬化症,肌萎缩性侧索硬化症,亨廷顿病,自闭症谱系障碍,注意力缺陷多动症,头痛,癫痫,脊髓损伤,缺血性中风,睡眠障碍。
摘要: Background: Melatonin is a molecule with numerous properties applicable to the treatment of neurological diseases. Among these properties are the following: potent scavenger of oxygen and nitrogen reactive species, anti-inflammatory features, immuno-enhancing nature, and modulation of circadian rhythmicity. Furthermore, low concentrations of melatonin are usually found in patients with neurological diseases and mental disorders. The positive results obtained in experimental models of diverse pathologies, including diseases of the nervous system (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, epilepsy, headaches, etc.) as well as mental and behavioural disordes (e.g., autism spectrum disorders, attention-deficit hyperactivity disorders, etc.), have served as a basis for the design of clinical trials to study melatonin's possible usefulness in human pathology, although the satisfactory results obtained from the laboratory “bench” are not always applicable to the patient's “bedside”.
Objective: In this article, we review those papers describing the results of the administration of melatonin to humans for various therapeutic purposes in the field of neuropathology.
Conclusion: Clinical trials with strong methodologies and appropriate doses of melatonin are necessary to support or reject the usefulness of melatonin in neurological diseases.
Export Options
About this article
Cite this article as:
Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders, Current Medicinal Chemistry 2017; 24 (35) . https://dx.doi.org/10.2174/0929867324666170718105557
DOI https://dx.doi.org/10.2174/0929867324666170718105557 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
2-Arylindoles: A Privileged Molecular Scaffold with Potent, Broad-Ranging Pharmacological Activity
Current Medicinal Chemistry Ivabradine: The Hope for a Good Treatment of Ischemic Heart Disease
Current Medicinal Chemistry Characterisation of a Neural Teratogenicity Assay Based on Human ESCs Differentiation Following Exposure to Valproic Acid
Current Medicinal Chemistry The Hippocampal Autophagic Machinery is Depressed in the Absence of the Circadian Clock Protein PER1 that may Lead to Vulnerability During Cerebral Ischemia
Current Neurovascular Research Changes in Psychiatric Diagnoses During the Transition Phase from Childhood to Adulthood in a Group of Patients with Intellectual Disability
Adolescent Psychiatry Reacting to Stress: Radical Cellular Pathways for Novel Drug Development
Current Neurovascular Research Ester Prodrugs of Ketoprofen: Synthesis, In Vitro Stability, In Vivo Biological Evaluation and In Silico Comparative Docking Studies Against COX-1 and COX-2
Current Drug Discovery Technologies TRP Channels: New Potential Therapeutic Approaches in CNS Neuropathies
CNS & Neurological Disorders - Drug Targets Bhasma: Indian Perspective of Nanomedicinal Technology
Recent Patents on Nanomedicine Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Inhibition of Monoamine Neurotransmitter Transporters andCentral Nervous System Stimulation Induced by Synthetic Local Anesthetics and Cocaine: A Comparative Review
Current Medicinal Chemistry - Central Nervous System Agents Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors
Current Drug Metabolism Editorial [Hot topic: Adenosine Receptor Ligands: Where Are We, and Where Are We Going? (Guest Editors: Tiziano Tuccinardi and Adriano Martinelli)]
Current Topics in Medicinal Chemistry Fetal Origins of Cardiovascular Disease
Current Cardiology Reviews AMPA Receptor Antagonists with Additional Mechanisms of Action: New Opportunities for Neuroprotective Drugs?
Current Pharmaceutical Design Recent Progress in the Pharmacology of Imidazo[1,2-a]pyridines
Mini-Reviews in Medicinal Chemistry Recent Progress in Transition-Metal-Catalyzed C-N Cross-Couplings: Emerging Approaches Towards Sustainability
Current Organic Synthesis Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors
Current Topics in Medicinal Chemistry Pharmacotherapy of Obesity - Benefit, Bias and Hyperbole
Current Medicinal Chemistry Adenosine Receptor Ligands-Recent Developments Part I. Agonists
Current Medicinal Chemistry